| Open Document File Size: 948,17 KBShare Result on Facebook
Company AEs / Astex Pharmaceuticals Inc. / AT13387 Overcomes / / Country United Kingdom / United States / / Event M&A / FDA Phase / / MedicalCondition Tumor / vomiting / fatigue / Crizotinib Relative Tumor Volume Tumor / cancer / ALKPositive Crizotinib-Resistant Xenograft H2228 tumor / NSCLC / resistant tumors / tumour / / MedicalTreatment Chemotherapy / / Person Keisha Hearn / Mohammad Azab / Harold Keer / Aurelie Courtin / Aram Oganesian / Nicola Wallis / Tomoko Smyth / John Lyons / / Product crizotinib / HSP90 / / Technology Chemotherapy / /
SocialTag |
Combination of HSP90 inhibitor onalespib (AT13387) with crizotinib to treat or delay resistance in NSCLC: Preclinical and Clinical Investigations. Harold Keer, Tomoko Smyth, Aurelie Courtin, Keisha Hearn, John Lyons, Nic